Lingyan Ping
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lingyan Ping has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Yuqin Song
Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing 100142, China
2 shared publications - Hui Yu
Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing 100142, China
1 shared publication - Jie Chen
Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing 100142, China
1 shared publication - Jin Chai
Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing 100142, China
1 shared publication - Jin Chai
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma Peking University Cancer Hospital & Institute Beijing China
1 shared publication - Jun Zhu
Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education) Peking University Cancer Hospital & Institute Beijing China
1 shared publication
Latest Publications
- Open Access
- 19 August 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (16) , 6408
Diagnosis-to-Treatment Interval Reflects Clinical Urgency and Disease Burden in T-Lymphoblastic Lymphoma: A Multicenter Cohort Study
Objective: Diagnosis-to-treatment interval (DTI) has been investigated in several lymphoma subtypes, but its significance in T-lymphoblastic lymphoma (T-LBL) remains unclear. We evaluated whether DTI reflects clinical urgency, disease burden and early outcomes in newly diagnosed T-LBL. Methods: We retrospectively analyzed 220 patients with newly diagnosed, mass-dominant, and histologically diagnosed T-LBL treated at four centers between 2003 and 2025. DTI was operationally defined as the interval from diagnostic biopsy to first systemic anti-lymphoma therapy and was primarily analyzed as a continuous variable per 7-day increase. Descriptive DTI groups were <15, 15–29 and ≥30 days. Results: Median DTI was 20 days (interquartile range [IQR], 14–32). Shorter DTI was associated with advanced stage, elevated lactate dehydrogenase (LDH), multiple extranodal involvement, central nervous system (CNS) involvement, B symptoms, lower hemoglobin and higher International Prognostic Index (IPI) score. CNS involvement remained independently associated with DTI < 15 days. In adjusted analyses, each 7-day increase in DTI was associated with lower odds of early treatment failure within 2 years (odds ratio [OR] 0.72, 95% confidence interval [CI] 0.58–0.88), lower hazards of progression-free survival (PFS) events (hazard ratio [HR] 0.84, 95% CI 0.74–0.94) and lower mortality (HR 0.84, 95% CI 0.73–0.98), but not complete response. Conclusions: Shorter DTI appears to reflect clinical urgency and disease burden rather than a causal effect of early treatment.
- 19 August 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (16) , 6408
Open AccessDiagnosis-to-Treatment Interval Reflects Clinical Urgency and Disease Burden in T-Lymphoblastic Lymphoma: A Multicenter Cohort Study
Objective: Diagnosis-to-treatment interval (DTI) has been investigated in several lymphoma subtypes, but its significance in T-lymphoblastic lymphoma (T-LBL) remains unclear. We evaluated whether DTI reflects clinical urgency, disease burden and early outcomes in newly diagnosed T-LBL. Methods: We retrospectively analyzed 220 patients with newly diagnosed, mass-dominant, and histologically diagnosed T-LBL treated at four centers between 2003 and 2025. DTI was operationally defined as the interval from diagnostic biopsy to first systemic anti-lymphoma therapy and was primarily analyzed as a continuous variable per 7-day increase. Descriptive DTI groups were <15, 15–29 and ≥30 days. Results: Median DTI was 20 days (interquartile range [IQR], 14–32). Shorter DTI was associated with advanced stage, elevated lactate dehydrogenase (LDH), multiple extranodal involvement, central nervous system (CNS) involvement, B symptoms, lower hemoglobin and higher International Prognostic Index (IPI) score. CNS involvement remained independently associated with DTI < 15 days. In adjusted analyses, each 7-day increase in DTI was associated with lower odds of early treatment failure within 2 years (odds ratio [OR] 0.72, 95% confidence interval [CI] 0.58–0.88), lower hazards of progression-free survival (PFS) events (hazard ratio [HR] 0.84, 95% CI 0.74–0.94) and lower mortality (HR 0.84, 95% CI 0.73–0.98), but not complete response. Conclusions: Shorter DTI appears to reflect clinical urgency and disease burden rather than a causal effect of early treatment.
- Open Access
Clinical Characteristics and Prognosis of Primary Central Nervous System Lymphoma: A Retrospective Analysis
Background: Primary central nervous system lymphoma (PCNSL) is a rare extranodal lymphoma characterized by a poor prognosis due to high relapse rates and a lack of standardized treatment. This study aimed to evaluate the impact of induction/consolidation therapy on long-term survival and to provide extended follow-up data. Methods: In this retrospective analysis, 140 immunocompetent patients with diffuse large B-cell PCNSL (DLBCL-PCNSL) treated at two centers between 2014 and 2024 were enrolled. Treatment efficacy was assessed based on baseline characteristics, therapeutic regimens, and treatment response. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method, and prognostic factors were identified using multivariate Cox proportional hazards regression models. Results: With a median follow-up of 5.3 years (range: 0.1–11.0 years), the 2- and 5-year PFS rates were 50.4% (95% CI: 42.1–60.2) and 34.1% (95% CI: 25.5–45.0), respectively, while the corresponding OS rates were 85.3% (95% CI: 79.4–91.6) and 60.8% (95% CI: 52.0–71.1). No survival plateau was observed. Among patients, 94% received methotrexate-based induction therapy: 94 received rituximab–methotrexate–temozolomide (R-MT) and 17 received MT alone, with 2-year PFS rates of 57.7% and 39.7%, respectively. Overall, 75% of patients achieved remission (CR/CRu/PR) after induction, and among these, 55% underwent consolidation therapy, predominantly autologous stem cell transplantation (ASCT, 90%) or whole-brain radiotherapy (10%). Patients receiving ASCT exhibited superior survival outcomes compared to those who did not. Conclusions: R-MT induction combined with ASCT consolidation is associated with improved survival in PCNSL, although relapse risk remains substantial. Outcomes remain poor in refractory subgroups, highlighting the need for novel therapeutic strategies.
Open AccessClinical Characteristics and Prognosis of Primary Central Nervous System Lymphoma: A Retrospective Analysis
Background: Primary central nervous system lymphoma (PCNSL) is a rare extranodal lymphoma characterized by a poor prognosis due to high relapse rates and a lack of standardized treatment. This study aimed to evaluate the impact of induction/consolidation therapy on long-term survival and to provide extended follow-up data. Methods: In this retrospective analysis, 140 immunocompetent patients with diffuse large B-cell PCNSL (DLBCL-PCNSL) treated at two centers between 2014 and 2024 were enrolled. Treatment efficacy was assessed based on baseline characteristics, therapeutic regimens, and treatment response. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method, and prognostic factors were identified using multivariate Cox proportional hazards regression models. Results: With a median follow-up of 5.3 years (range: 0.1–11.0 years), the 2- and 5-year PFS rates were 50.4% (95% CI: 42.1–60.2) and 34.1% (95% CI: 25.5–45.0), respectively, while the corresponding OS rates were 85.3% (95% CI: 79.4–91.6) and 60.8% (95% CI: 52.0–71.1). No survival plateau was observed. Among patients, 94% received methotrexate-based induction therapy: 94 received rituximab–methotrexate–temozolomide (R-MT) and 17 received MT alone, with 2-year PFS rates of 57.7% and 39.7%, respectively. Overall, 75% of patients achieved remission (CR/CRu/PR) after induction, and among these, 55% underwent consolidation therapy, predominantly autologous stem cell transplantation (ASCT, 90%) or whole-brain radiotherapy (10%). Patients receiving ASCT exhibited superior survival outcomes compared to those who did not. Conclusions: R-MT induction combined with ASCT consolidation is associated with improved survival in PCNSL, although relapse risk remains substantial. Outcomes remain poor in refractory subgroups, highlighting the need for novel therapeutic strategies.